




# HIFI SOLUTIONS FOR CANCER GENOMICS

## A more complete understanding of cancer biology and potential clinical outcomes


In order to fulfill the promise of cancer precision medicine, a more complete understanding of the complexity of cancer biology is critical. Crucial to this knowledge are multiomic tools that can accurately and comprehensively profile all types of somatic and germline variation, including rare somatic variants at low frequency that can indicate emerging recurrence or subclonal drug resistance. Existing methods can typically only capture only a fraction of this variation, requiring multiple assays and technologies to gain the whole picture. Highly accurate long-read sequencing from PacBio® allows cancer researchers to characterize the complete spectrum of cancer variation in a single assay, yielding a clearer view of its biology, helping to identify new therapeutic targets and inform clinical decision making.





## What is HiFi sequencing?

PacBio HiFi sequencing unites long reads and accuracy, giving you the highest quality genomic data. When it comes to your cancer research, why compromise with technologies that provide limited information?



## The benefits of HiFi reads



Long read lengths



Low DNA input requirements and easy library prep



Low coverage requirements



Small file sizes to minimize compute time




Supported analysis tools consolidated into a single pipeline



High read accuracy




Fully automated sequencing and no manual washing steps



A single technology solution



# Explore the full range of cancer variants for biomarker detection and therapeutic development






# Reveal hidden variation with more complete cancer genomes and epigenomes

Characterize the full spectrum of variants and biomarkers with a single assay

- **Discover** more structural variants with long reads while maintaining the accuracy needed for small variant detection.
- **Resolve and assign** variants to haplotypes, meaning you can differentiate between *cis* and *trans* mutations to identify compound heterozygosity.
- **Detect 5mC, 5hmC, and 6mA methylation** in a single assay to reveal epigenetic silencing and changes in chromatin accessibility linked to tumor growth or treatment resistance.
- **Optimize** somatic variant detection with a complete bioinformatics workflow<sup>4</sup> for long-read tumor/normal whole genome sequencing.

Understanding the complexity of cancer genomes requires methods that can reveal the full breadth of cancer genomic variation, from SNVs and indels to structural variants (SVs), copy number variants (CNVs), and differential methylation. HiFi long-read sequencing allows cancer researchers to characterize the complete spectrum of somatic and germline variation, including SVs and methylation, yielding a clearer view of cancer biology and helping to identify new therapeutic targets and inform clinical decision making.

For example, researchers at Children's Mercy Kansas City identified clinically relevant SVs in pediatric leukemia samples using HiFi sequencing that were missed by routine clinical approaches<sup>1</sup>, providing insight that impacted treatment decisions. Researchers at University of Melbourne discovered tumor-specific *BRCA2* promoter hypermethylation as a second hit leading to loss of function of the tumor suppressor in sarcoma<sup>2</sup>. Finally, Fiber-seq pioneers at University of Washington revealed changes in chromatin accessibility, including enhancer hijacking and biased X-chromosome inactivation, in a Mendelian condition involving bilateral retinoblastomas<sup>3</sup>.






# Understand mechanisms of RNA dysregulation with bulk + single-cell transcriptomes

Reveal more of the tumor transcriptome through comprehensive detection of isoforms, fusions, and expressed mutations

- **Discover** RNA isoforms as a source of cancer biomarkers and drug targets
- **Identify** known, novel, and complex RNA fusions with more accurate breakpoints and a complete sequence readout of associated fusion transcripts.
- **Detect** expressed mutations in RNA for genotyping and neoantigen discovery

While cancer is often considered a disease of the genome, much of the effects of cancer-causing mutations are expressed at the level of RNA. Current short-read methods rely on transcript assembly to identify isoforms and fusions, but fail to uncover much of the variation present in the tumor transcriptome. Long-read RNA sequencing with the Iso-Seq® method powered by Kinnex™ kits offers an exceptional look at alternative splicing, fusion events, and expressed somatic mutations, elevating our understanding of RNA dysregulation in cancer.

For example, a study published in *Science Advances*<sup>5</sup> showed that bulk long-read RNA sequencing with Iso-Seq in HER2+ breast cancer discovered 2.5× the number of novel isoforms. These isoforms were enriched in oncogenes and led to altered protein domains and localization. Another *Nature Communications* study<sup>6</sup> used PacBio single-cell RNA sequencing in ovarian cancer to discover a novel fusion that was previously miscategorized as an overexpression of the 3' fusion partner in short-read data. Finally, single-cell RNA sequencing with Iso-Seq in colorectal cancer discovered many tumor-specific isoforms<sup>7</sup>, which when combined with mass spectrometry and HLA binding affinity could be used as neoantigens to develop cancer vaccines.






## Sequence on your terms

Whether you need the scalability of the Revio® system or the flexibility of the Vega™ system, power your research with PacBio HiFi-long read sequencing

### Revio long-read system


- The Revio system with SPRQ™-Nx chemistry delivers an impressive 120 Gb per SMRT® Cell, making it the clear choice for broad-scale population genomics or precision health programs.
- With independent sequencing stages, you can run up to 4 SMRT Cells simultaneously, enabling multiomic assays on a single platform.
- Only 500 ng of sample input allows access to samples and applications previously not possible.
- The Revio system is ideal for human genomes, single cell sequencing, full-length isoform sequencing, and human methylation profiles.

#### SMRT Cell 1



Tumor WGS (40×)  
+ native 5mC and 6mA

#### SMRT Cell 2




Tumor WGS (40×)  
+ native 5mC and 6mA

#### SMRT Cell 3



Normal WGS (40×)  
+ native 5mC and 6mA

#### SMRT Cell 4




Kinnex scRNA-seq  
(100-120M reads)

Multitomic tumor profiling in a single run

### Vega long-read benchtop system

- The Vega system delivers 60 Gb of premium HiFi data per SMRT Cell – accessibly priced to enable your application of choice.
- A single SMRT Cell configuration puts you in full control for streamlined, immediate sequencing.
- Innovative Revio technology packed to fit on a benchtop – equivalent HiFi data in a reduced instrument footprint.
- The Vega system is ideal for full-length isoform sequencing and targeted panels like the PureTarget™ repeat expansion kit.



## Ready to get started with PacBio sequencing?



Learn more about cancer genomics:  
[pacb.com/cancer-genomics](https://pacb.com/cancer-genomics)



Explore cancer Sequencing 101 videos:  
[pacb.com/cancer-playlist](https://pacb.com/cancer-playlist)




Explore the cancer breakthrough interactive experience:  
[pacb.com/cancer-interactive](https://pacb.com/cancer-interactive)



Connect with a PacBio scientist to get started:  
[pacb.com/scientist](https://pacb.com/scientist)

1. Lansdon, L. A., et al. (2024). **Successful classification of clinical pediatric leukemia genetic subtypes via structural variant detection using HiFi long-read sequencing.** *medRxiv*, 2024-11. <https://doi.org/10.1101/2024.11.05.24316078>
2. Chua, K.P., McLaughlin, I., Hofmann, O., Stewart, K.P., Baybayan, P., Bibliowicz, J., Grimmond, S., Kronenberg, Z., Eberle, M.A. (2024). **Somatic variant workflow with HiFi sequencing provides new insights in highly challenging cancer cases.** Presented at the 2024 AACR Annual Meeting. San Diego, California. April 5-10, 2024.
3. Vollger, M. R., et al. (2025). **Synchronized long-read genome, methylome, epigenome and transcriptome profiling resolve a Mendelian condition.** *Nature Genetics*, 1-11. <https://doi.org/10.1038/s41588-024-02067-0>
4. Chua, K. P., et al. (2024). **Somatic variant workflow with HiFi sequencing provides new insights in highly challenging cancer cases.** *Cancer Research*, 84(6\_Supplement), 2934-2934. <https://doi.org/10.1158/1538-7445.AM2024-2934>
5. Veiga, D. F., Nesta, et al. (2022). **A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer.** *Science Advances*, 8(3), eabg6711. <https://doi.org/10.1126/sciadv.abg6711>
6. Dondi, A., Lischetti, U., et al. (2023). **Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer.** *Nature Communications*, 14(1), 7780. <https://doi.org/10.1038/s41467-023-43387-9>
7. Li, Z., Zhang, B., Chan, J. J., et al. (2024). **An isoform-resolution transcriptomic atlas of colorectal cancer from long-read single-cell sequencing.** *Cell Genomics*, 4(9). <https://doi.org/10.1016/j.xgen.2024.100641>
8. Revil, T. et al. (2024). **Improved detection of low frequency mutations in ovarian and endometrial cancers by utilizing a highly accurate sequencing platform.** *Cancer Research*, 84(6\_Supplement), 2443-2443. <https://doi.org/10.1158/1538-7445.AM2024-2443>



Research use only. Not for use in diagnostic procedures. 2026 Pacific Biosciences of California, Inc. ("PacBio"). All rights reserved. Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certain notices, terms, conditions and/or use restrictions may pertain to your use of PacBio products and/or third-party products. Refer to the applicable PacBio terms and conditions of sale and to the applicable license terms at [pacb.com/license](https://pacb.com/license). Pacific Biosciences, the PacBio logo, PacBio, Circulomics, Omniome, SMRT, SMRTbell, Iso-Seq, Sequel, Nanobind, Revio, Revio SPRQ, Kinnex, PureTarget, SPRQ, Vega and Vega SPRQ are trademarks of PacBio.